Tirzepatide dose escalation causes functional small bowel obstruction in surgically naïve patient
Background
Type 2 diabetes mellitus and obesity are global health crises, driving demand for effective pharmacotherapies. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, like tirzepatide, have revolutionized treatment by improving glycemic control and promoting significant weight loss. These agents exert their effects partly by slowing gastric emptying and modulating gut motility, which can lead to common gastrointestinal side effects such as nausea, vomiting, and constipation. However, severe complications like small bowel obstruction (SBO) are rare, particularly functional SBO in patients without a history of abdominal surgery, posing a diagnostic challenge. This case highlights a critical gap in understanding the full spectrum of tirzepatide's gastrointestinal adverse events.
Study Design
This case report details a 60-year-old female patient with type 2 diabetes mellitus and obesity who developed symptoms consistent with small bowel obstruction following tirzepatide dose escalation. The patient was surgically naïve, meaning she had no prior abdominal surgeries that would typically predispose to mechanical SBO. The diagnostic process involved a comprehensive clinical evaluation to differentiate between mechanical and functional obstruction. The management strategy focused on non-operative approaches, utilizing objective tools such as the water-soluble contrast challenge to confirm the diagnosis of functional obstruction and guide conservative treatment, thereby avoiding unnecessary surgical intervention. Specific doses or escalation schedules for tirzepatide were not detailed in the abstract.
Results
The patient experienced functional small bowel obstruction directly attributed to tirzepatide dose escalation, which clinically mimicked a mechanical obstruction.
Key Findings
- Tirzepatide dose escalation can induce functional small bowel obstruction.
- This obstruction can mimic mechanical obstruction, even in surgically naïve patients.
Water-soluble contrast challengeis an objective tool for diagnosis.- Non-operative management is crucial to avoid unnecessary surgery.
- High clinical suspicion for tirzepatide-induced SBO is warranted.
Why It Matters
This case underscores the importance of considering tirzepatide as a potential cause of functional small bowel obstruction, even in patients without a surgical history. For clinicians, this means a high index of suspicion is warranted when patients on GLP-1R/GIP-R agonists present with SBO symptoms, necessitating a thorough medication review. Adopting non-operative management strategies, guided by tools like the water-soluble contrast challenge, can prevent unnecessary surgical interventions, reducing patient morbidity and healthcare costs. For peptide users, this highlights the need for careful dose titration and awareness of severe, albeit rare, gastrointestinal side effects. While a rare complication, this finding suggests that the protocol for tirzepatide use should include vigilance for severe GI symptoms beyond common nausea or constipation, especially during dose escalation.
tirzepatide
small-bowel-obstruction
gastrointestinal
adverse-event
case-report
glp-1-agonist